Skip to content

Press Release · Press Releases

Lucid Diagnostics to Participate in the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum

Issued by PR Newswire

Image: PR Newswire

NEW YORK, Nov. 4, 2026 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced that it will participate in the Canaccord Genuity...

This press release summary is reproduced from the issuer's public feed.

Read the full release at PR Newswire

Original publisher: PR Newswire

Spotted an error? Request a correction · Corrections Policy

Related stories